Microbial Genomics as a Catalyst for Targeted Antivirulence Therapeutics
Open Access
- 13 April 2021
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Medicine
Abstract
Virulence arresting drugs (VAD) are an expanding class of antimicrobial treatment that act to “disarm” rather than kill bacteria. Despite an increasing number of VAD being registered for clinical use, uptake is hampered by the lack of methods that can identify patients who are most likely to benefit from these new agents. The application of pathogen genomics can facilitate the rational utilization of advanced therapeutics for infectious diseases. The development of genomic assessment of VAD targets is essential to support the early stages of VAD diffusion into infectious disease management. Genomic identification and characterization of VAD targets in clinical isolates can augment antimicrobial stewardship and pharmacovigilance. Personalized genomics guided use of VAD will provide crucial policy guidance to regulating agencies, assist hospitals to optimize the use of these expensive medicines and create market opportunities for biotech companies and diagnostic laboratories.This publication has 58 references indexed in Scilit:
- Precision Medicine and Precision Public Health in the Era of Pathogen Next-Generation SequencingThe Journal of Infectious Diseases, 2019
- Patient-Customized Oligonucleotide Therapy for a Rare Genetic DiseaseThe New England Journal of Medicine, 2019
- Targeting Mannitol Metabolism as an Alternative Antimicrobial Strategy Based on the Structure-Function Study of Mannitol-1-Phosphate Dehydrogenase in Staphylococcus aureusmBio, 2019
- Are Global Health Systems Ready for Transformative Therapies?Value in Health, 2019
- Engineered toxin–intein antimicrobials can selectively target and kill antibiotic-resistant bacteria in mixed populationsNature Biotechnology, 2019
- Different drugs for bad bugs: antivirulence strategies in the age of antibiotic resistanceNature Reviews Drug Discovery, 2017
- Inhibitors of TonB Function Identified by a High-Throughput Screen for Inhibitors of Iron Acquisition in Uropathogenic Escherichia coli CFT073mBio, 2014
- Targeting virulence: can we make evolution-proof drugs?Nature Reviews Microbiology, 2014
- Anti-virulence strategies to combat bacteria-mediated diseaseNature Reviews Drug Discovery, 2010
- Safety and Pharmacokinetics of Urtoxazumab, a Humanized Monoclonal Antibody, against Shiga-Like Toxin 2 in Healthy Adults and in Pediatric Patients Infected with Shiga-Like Toxin-Producing Escherichia coliAntimicrobial Agents and Chemotherapy, 2010